WO2011055388A2 - Matrice polymère utilisée en tant que pansement - Google Patents

Matrice polymère utilisée en tant que pansement Download PDF

Info

Publication number
WO2011055388A2
WO2011055388A2 PCT/IN2010/000727 IN2010000727W WO2011055388A2 WO 2011055388 A2 WO2011055388 A2 WO 2011055388A2 IN 2010000727 W IN2010000727 W IN 2010000727W WO 2011055388 A2 WO2011055388 A2 WO 2011055388A2
Authority
WO
WIPO (PCT)
Prior art keywords
iodine
polymer matrix
matrix
range
polyvinyl alcohol
Prior art date
Application number
PCT/IN2010/000727
Other languages
English (en)
Other versions
WO2011055388A3 (fr
Inventor
Ashok Kumar
Era Jain
Original Assignee
Indian Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Institute Of Technology filed Critical Indian Institute Of Technology
Publication of WO2011055388A2 publication Critical patent/WO2011055388A2/fr
Publication of WO2011055388A3 publication Critical patent/WO2011055388A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/202—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with halogen atoms, e.g. triclosan, povidone-iodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the present invention relates to a macroporous polymer matrix for controlled release of active ingredient and a process of preparation thereof.
  • Iodine is one of the oldest and effective antiseptic agents. It is a powerful microbicidal with a broad antimicrobial spectrum including fungi and medium viruses. A number of antiseptic preparations for wound care are commercially available which utilizes iodine as antimicrobial agent.
  • the antimicrobial activity of iodine partly depends upon its ability to penetrate the cell walls of microorganisms rapidly, and block certain essential hydrogen-bonding in amino acids. Also, it has a powerful, oxidizing effect on S-H, -S- S- groups, which are essential factors in protein production.
  • Iodine is designated as an intermediate germicide only because spores are not readily killed with weak concentrations. However, iodine has the greatest de-germing efficiency compared to the other halogens, chlorine and bromine, since it is deactivated by proteins at least three times slower than chlorine and four times slower than bromine. Therefore, under normal conditions of use where there is the presence of large amounts of dissolved proteins in blood, serum, or sputum, iodine would not be rendered ineffective.
  • Iodine has the additional advantage that its disinfecting properties are independent of the pH value of its environment. Therefore, unlike chlorine, for example, iodine would not be rendered ineffective in an acid pH. It would likewise not be deactivated quickly in an alkaline pH.
  • iodine Some of the limitation for the germicidal use of iodine is its high aqueous insolubility (0.034% at 25° C.) and high vapor pressure. While the aqueous solubility of iodine may be increased through the use of alcohol (as for example, tincture of iodine) or through the use of inorganic metallic salts as solubilizing agents (as for example, sodium iodide and/or potassium iodide in the preparation of Lugols' Solution), such iodine solutions also possess the same toxic tissue manifestations which generally limit the use of iodine germicidal solutions. Generally a simple iodine solution in form a tincture-iodine is highly cytotoxic if applied directly on wounds.
  • Iodophors are loose complexes of elemental iodine or triiodide, solubilizers, and a polymeric carrier that serves, not only to increase the solubility of the iodine but also to control the release of iodine in a sustained manner.
  • the general class of organic iodophor compounds comprises two distinct polymer groups; the first group consisting of only one member, polyvinylpyrrolidone, which is a non-detergent, non-ionic and non-surface active polymer, the second group comprises the broad variety of detergent-surface active polymers including non-ionic, anionic and cationic surface active polymers. Both polymer groups are complexed with elemental iodine to form the iodophor.
  • the general method for the preparation of an iodophor complex is to bring into intimate contact, elemental diatomic iodine with the selected polymer either in the dry or powder form or in the presence of a suitable solvent. Heat may be used to accelerate complex formation.
  • the iodophor complex of the respective polymeric carrier with iodine is obtained in a certain reproducible proportions of one to the other.
  • the carriers heretofore, have been neutral, water soluble polymers, with mainly polyvinylpyrrolidones as principal commercialized polymer.
  • Polyether glycols, polyacrylic acids, polyamides, polyoxyalkylenes, starches and polyvinylalcohol (PVA) also form iodophors.
  • the most commonly used iodophor is polyvinylpyrrolidone also known as povidone-iodine.
  • Patent No. US 5,242,585 describes about an iodophor of PVP/I 2 in form of a free flowing aqueous soluble lightly crosslinked powder, for controlling the release of iodine from PVP based iodophor preparations.
  • These iodophor complexes form micellar aggregates, which are dispersed upon dilution with body fluids or water and the iodine linkage to the polymer is progressively weakened until the iodine can be regarded as free to generate antimicrobial concentrations.
  • Betadine available as solution or cream. These iodine preparations have advantage over free iodine in that they greatly reduce the irritation to the tissue, unpleasant odour, staining of the tissue and corrosion of metal surfaces. The sustained release properties of PVP/I 2 iodophors have encouraged their usage in preoperative skin preparations surgical scrubs, washes douches, lotions and ointments.
  • aqueous based iodophors Although quite effective as antimicrobial agent these aqueous based iodophors have limitations in terms of limited iodine reserves and dilution factors leading to a disinfecting effect for relatively short period of time. Most water miscible broad spectrum antimicrobials exhibit this deficiency. Since the iodophors are water soluble they tend to dissipate their antimicrobial action quickly. The concentrations of iodine in water based systems can be much higher than what is required for its antimicrobial intent and iodine is dissipated by side reactions resulting in depletion of iodine reservoir leading to recolonization of microbes at wound site.
  • N-vinylpyrrolidone N-vinylpyrrolidone
  • the iodophor-based adhesive film provides a sterile operative surface, and acts as a barrier to isolate the incision from contaminating skin flora. This product is for use as an incisible self- adhering drape and is not intended for wound healing dressings or wound packings.
  • Iodophor preparations are described in terms of available or titratable iodine which is considered to be the iodine released from the complex to exert its germicidal action. However, such available iodine determinations do not either reflect the total iodine content of the iodophor or its germicidal potency. Iodophor solutions are also categorized on the basis of the amount of iodine extracted into an immiscible organic solvent which is expressed as the distribution coefficient for the preparation. Such extracted iodine is defined as uncomplexed or free iodine and is interpreted to reflect iodophor integrity. The uncomplexed iodine is postulated to be the cause of toxic responses, unstable and malodorous preparations and the distribution coefficient became the general measure to predict stability of the preparation on storage as well as the occurrence of toxic tissue responses.
  • Patent No. US 4,946,673 describes about methods to determine the equilibrium iodine content responsible for microbicidal activity in aqueous iodophor preparations and methods to control the same. It is described that controlling the equilibrium iodine content in aqueous solutions preferably between 2-15 ppm provides predetermined germicidal activity.
  • iodine interacts with certain physiologic organic compounds, proteins, carbohydrates and reducing substances such as sulfhydryl groups present in blood, pus and other biologic fluids. These substances present in living cellular materials consume iodine to deplete both the equilibrium iodine and the reservoir iodine of the iodophor solution as it is used in degerming practice.
  • the principle iodine resource for the regeneration of equilibrium iodine is the predominant iodine species I 3 " , which exists both in the free state as well as being bound to the polar hydrophilic centers of the povidone polymer.
  • the polymer povidone will combine with about one mol of iodine for each mol of monomer and such combination involves an ionic bond.
  • certain iodine anion as for example I5 “ and I 7 " form by the selective complexing between elemental iodine and the appropriate precursor derivative iodine anion, the recovery of iodine from I 3 ⁇ anion is the major iodine resource species to be considered for equilibrium iodine regeneration.
  • iodine Low concentrations of iodine react relatively slowly as compared with proteins in general arid therefore it remains available to react with bacteria to which it generally has greater affinity. It is in this way that iodine can exhibit its unique advantageous selectivity towards microorganisms while maintaining a very low cytotoxicity to the host cells.
  • Patent No. US 5,071,648 describes polymerizing soluble PVA to form insoluble acetals in the form of foams, sheets or gels, and subsequently forms less soluble iodine complexes with these acetals with solutions of iodine, iodides, borates or their combinations.
  • Such complexes of polyvinyl alcohol and iodine have a low solubility such that it releases iodine in a sustained and a controlled manner in an amount which will kill germ cells but not damage living tissue.
  • An antimicrobial borate material may also be complexed with the polyvinyl alcohol.
  • the complex may be with PVA or PVA acetal film, sponge, foam or gel and used as a wound dressing.
  • the iodine is preferably complexed with hydroxylated polyvinyl acetal sponge and topically used. Additionally, the complex may be combined with a matrix, such as cloth or non-woven material.
  • Patent No. US 5,073,614 describes preparation of strongly swellable, moderately or lightly crosslinked PVP having a predetermined aqueous swelling parameter and a defined viscosity which had effective thickener and gelling properties.
  • the reaction product of water soluble or water-insoluble PVP with elemental iodine is marketed as a brown powder which contains about 1 1% of available iodine, i.e. active iodine, which can be titrated with sodium thiosulfate, and, in addition, contains about 5.5% of iodine in the form of iodide.
  • the iodine bonding in the PVP- iodine complex is so strong that an iodine odor is no longer perceptible and a moist potassium iodide/starch paper introduced into the gas space above the PVP-iodine no longer acquires a color.
  • the measure employed to assess whether the iodine is sufficiently firmly bonded is the partition coefficient of the iodine between an aqueous PVP-iodine solution and heptane, and this coefficient, as described, for example, in Patent No. US 3,028,300 should be about 200. Further it is necessary that in its formulations, in particular, in aqueous solution, the PVP-iodine complex should lose very little available iodine on storage, i.e. it should be very stable.
  • One aspect of the present invention provides a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v polyvinylpyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate.
  • Another aspect of the present invention provides a process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said process comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone alone or in combination with polyvinyl alcohol at a temperature in the range of about -10°C to -20°C for a period of about 10 to 20 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain said polymer matrix.
  • Figure 1 shows a macroporous polymer matrix of polyvinylpyrrolidone-iodine a) The pictures from left are polymer matrix; PVP/I 2 polymer matrix; and a PVP/I 2 in different formats; b) PVP/I 2 -gelatin bilayer.
  • Figure 2 shows a scanning electron microscopic image of polyvinyl pyrrolidone polymer matrix
  • Figure 3 shows a Polyvinyl pyrrolidone-Iodine layer germicidal activity against A) E. coli; B) Staphylococcus aureus.
  • the arrows indicate the zone of inhibition which in both the cases lies between 1.8 to 2 cm. (The diameter of the macroporous PVP/I 2 polymer matrix is 0.9cm)
  • Figure 4 shows cytotoxicity test results of PVP/I 2 polymer matrix assay using MTT.
  • Figure 5 shows rate of Iodine release from PVP-PEG Da-PVA-I 2 and PVP-PEG Da-I 2 DETAILED DESCRIPTION OF THE INVENTION
  • a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein thickness of the polymer matrix is in the range of about 0.5 mm to 20 mm.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein pore size of the polymer matrix is in the range of about ⁇ ⁇ to 250 ⁇ .
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polyethyleneglycol diacrylate is in the range of about 2% to 4% w/v preferably 2%.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polyvinylpyrrolidone is in the range of about 5% to 6% w/v preferably 5%.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polymeric matrix further comprises at least one active ingredient selected from a group consisting of antiseptic agents, antibacterial agents, antiviral agents, antipathogen agents, proteins, hormones, growth factors, immune modulators, enzymes and amino acids.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polymer matrix comprises a combination of polyvinyl pyrrolidone and polyvinyl alcohol and polyethyleneglycol diacrylate.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein ratio of the polyvinylpyrrolidone to said polyvinyl alcohol is in the range of 1 : 1 to 5: 1 preferably 1.25: 1.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polymeric matrix further comprises iodine.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polymeric matrix further comprises iodine, wherein ratio of the polymer matrix to iodine is in the range of 2: 1 to 40: lw/w preferably 5: 1 w/w.
  • the macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof, said matrix comprises 2% to 15% w/v N-vinyl pyrrolidone or a combination of N-vinyl pyrrolidone and polyvinyl alcohol and 2% to 8% polyethyleneglycol diacrylate, wherein the polymeric matrix further comprises iodine, wherein the polymer matrix is capable of releasing iodine in a sustained manner for a period of 48 hours.
  • One embodiment of the present invention provides the polymer matrix of the present invention, wherein the polymer matrix is attached with gelatin.
  • a process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone alone or in combination with polyvinyl alcohol at a temperature in the range of about -10°C to -20°C preferably at - 12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix.
  • the process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone at a temperature in the range of about -10°C to -20°C preferably at -12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix.
  • the process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone at a temperature in the range of about -10°C to -20°C preferably at -12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix and incubating said polyvinylpyrrolidone matrix with one or more active ingredient at a temperature in the range of about 70°C to 85°C preferably at about 75°C for a period of about 3 to 7 hours preferably for about 5 hours.
  • a process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone in combination with polyvinyl alcohol at a temperature in the range of about -10°C to -20°C preferably at -12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix.
  • a process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone in combination with polyvinyl alcohol at a temperature in the range of about -10°C to -20°C preferably at -12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix and subjecting said polyvinylpyrrolidone-polyvinyl alcohol matrix to 2 to 10 freeze thaw cycles at a temperature in the range of about -10°C to -30°C preferably at about f -20°C or a period of 5 to 20 hours.
  • a process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone in combination with polyvinyl alcohol at a temperature in the range of about -10°C to -20°C preferably at -12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix; subjecting the polyvinylpyrrolidone-polyvinyl alcohol matrix to 2 to 10 freeze thaw cycles at a temperature in the range of about -10°C to -30°C preferably at about f -20°C or a period of 5 to 20 hours and further comprises incubating said polyvinylpyrrolidone- , polyvinyl alcohol matrix with one or more active ingredient at a temperature in the range of about 20°C to 40°C
  • a process for preparation of a controlled release macroporous polymeric matrix for administrating one or more active ingredient to a subject in need thereof comprising polymerizing 2% to 15% w/v N-vinyl pyrrolidone in combination with polyvinyl alcohol at a temperature in the range of about -10°C to -20°C preferably at -12°C for a period of about 10 to 20 hours preferably for 16 hours in presence of 2% to 8% polyethyleneglycol diacrylate to obtain the polymer matrix; subjecting the polyvinylpyrrolidone-polyvinyl alcohol matrix to 2 to 10 freeze thaw cycles at a temperature in the range of about -10°C to -30°C preferably at about f -20°C or a period of 5 to 20 hours and further comprises incubating said polyvinylpyrrolidone- polyvinyl alcohol matrix with one or more active ingredient at a temperature in the range of about 20°C to 40°C preferably at
  • the macroporous polymer matrix of the present invention provides a solution to the problems associated with current drug delivery options.
  • the inventors have invented unique macroporous polymer matrices that allow convenient administration for the long-term sustained release of an active ingredient to a targeted site. This can allow the frequency of administrations to be reduced.
  • the slow degradation of polymer network will result in slow release of the drug.
  • the degraded polymer produces acidic by-products, slow degradation will minimize any inflammation that results from acidic by-products (lower localized concentration of acids), which is common with bioerodable polymeric material.
  • the macroporous polymer matrix of the present invention can be used a transdermal drug delivery system to administer one or more active ingredient to a subject in need thereof.
  • the present invention further provides a macroporous polymer matrix coupled with iodine for controlled release of iodine.
  • the present invention also provides a process of preparation of the macroporous polymer matrix.
  • the polymer matrix disclosed in the present invention comprises a polymer cross-linked by polyethylene glycol diacrylate.
  • the polymer used in the matrix is polyvinyl pyrrolidone or a combination of polyvinyl pyrrol idone and polyvinyl alcohol.
  • the polymer matrix disclosed in the present invention is capable of releasing iodine in a sustained manner.
  • the polymer matrix disclosed in the present invention can be used as an antiseptic wound dressing patch in the form of a bandage or thin sheet patch.
  • the polymer matrix is synthesized at sub zero temperatures in thin sheet format by free radical polymerization and cross-linking using polyethylene diacrylate.
  • the present invention provides a PVP-Iodine antiseptic epidermal patch which can be used like an adhesive bandage for superficial wounds and burns.
  • the antimicrobial hydrogel sheet will serve as a reservoir of iodine releasing iodine in a controlled manner.
  • the macroporous hydrogel sheets are advantageous in a manner that they have superior physical properties such as biocompatibility, softness, high absorption of body fluids; by itself they do not support growth of microorganism.
  • the iodine will not be washed out of complexes and remain active during the period of application thus repeated application is not required.
  • these hydrophilic matrices will serve as reservoir of iodine which can release iodine in a sustained manner as well as protect the wound.
  • the present invention describes a polymeric macroporous hydrogel wound dressing composed of PVP/I 2 in form of a hydrogel film or sheet.
  • a macroporous hydrogel film/patch composed of PVP/I 2 is intended to serve as moist wound dressing. Additionally, the complex may be combined with a matrix, such as cloth or non-woven material.
  • One further modification of the invention is the use of an interpenetrating network of PVP- PVA in form of macroporous hydrogel thin sheet as iodophors. These PVP-PVA interpenetrating hydrogel iodophor sheets provide a more sustained and controlled release of iodine than the PVP/1 2 macroporous hydrogel sheet alone.
  • An interpenetrating network is a combination of two polymers, in network form, of which at least one is synthesized and/or cross-linked in the immediate presence of the other without any covalent bonds between them. These polymers are closely related to other multicomponent materials, containing completely entangled chains, such as polymer blends, grafts and blocks. But, the IPN can swell in solvents without dissolving and can suppress creep and flow. Most IPNs are heterogeneous systems comprised of one rubbery phase and one glassy phase which produce a synergistic effect yielding either high impact strength or reinforcement, both of which are dependent on phase continuity.
  • hydrogel dressings are desirable, in part, because they provide protection against infectious agents. Hydrogel dressings are further desirable because wound exudates do not generally dry and consolidate with hydrogels or hydrogel laminates as with the case with traditional gauze dressings. Consequently, removal of a hydrogel dressing is usually neither painful nor detrimental to the healing process. It has been suggested that hydrogel dressings may be particularly desirable for treatment of burns because they may accelerate healing. Although the mechanism by which hydrogels stimulate healing is not fully elucidated, it is documented that the high water content of hydrogels enables them to effect an immediate cooling of the wound surface and to sustain the reduced temperature for up to six hours.
  • Maintaining a moist wound environment facilitates the wound-healing process.
  • the beneficial effects of a moist versus a dry wound environment include: prevention of tissue dehydration and cell death, accelerated angiogenesis, increased breakdown of dead tissue and fibrin, i.e., pericapillary fibrin cuffs, and potentiating the interaction of growth factors with their target cells.
  • pain is significantly reduced when wounds are covered with an occlusive dressing.
  • moisture in wounds would increase the risk of clinical infection.
  • Use of a moist wound dressing in form of a hydrogel containing an antiseptic agent like iodine will help to reduce the risk, of this contamination and promote wound healing.
  • a combination of hydrogel wound dressings with a bactericidal agent will have dual functionality of protecting the wound against infection and also faster wound healing.
  • One embodiment of the present invention provides a thin hydrogel sheet containing iodine complexed with composed of PVP-PEG and polyvinyl alcohol (PVA) in form of interpenetrating network of PVA and /or PVP.
  • PVA polyvinyl alcohol
  • One embodiment of the present invention provides a polymer matrix which overcomes the limitations of different topical water soluble formulations of iodine by complexing iodine to cross-linked macroporous hydrogel sheet and controlling iodine release for topical applications.
  • An important embodiment of the present invention is to provide an iodophor preparation in form of macroporous hydrogel sheets which can be used topically as wound dressing with or without the use of an adhesive secondary dressing.
  • the antiseptic iodophor macroporous hydrogel sheet disclosed in the present invention protect the wound against infection and also provide a soft elastic hydrogel protective covering which can absorb various body fluids and dose not leave back any residues of fibers in the wound.
  • One other advantage of this antiseptic macroporous wound dressing is that it dose not stick to the wound and can be removed easily without pain.
  • Thin sheets of macroporous polymeric hydrogel complexed to iodine also present the advantage that, they do not contaminate the wound site by leaving behind healing inhibiting foreign materials, such as lint particles from gauze, or petroleum ointment jelly vehicles, to contain topical antibiotics.
  • iodine As iodine is released, it is taken up by microbes forming an irreversible chemical reaction, killing the microbes. As released iodine is taken up, only then is more released, until equilibrium is maintained. A great reservoir of iodine is complexed in the PVP/I 2 system and because of its limited solubility is not readily released to side reactions causing rapid iodine depletion and resulting loss of effectiveness common to other iodophors. PVP/1 2 has been reported to have a reservoir of available iodine of about 10,000 PPM, of which only up to 35 PPM is available immediately.
  • PPM Since only as little as 0.2 PPM may be required for bactericidal effectiveness, while still preserving the health of host cells over a prolonged period, increasing the stability of the iodine complex is desirable. Microorganisms are more sensitive to iodine than healthy cells; therefore keeping the free iodine concentration low enough, creates selectivity towards the killing of microorganisms.
  • a combination of PVP and PVA reduces some of the disadvantages associated with PVP-I 2 complex alone and provides a better sustained release of iodine than the PVP/I 2 system.
  • PVA alone forms a very strong complex with Iodine thus at any given time the free iodine or equilibrium iodine content required for antimicrobial activity is lesser than the PVP/I 2 complexes.
  • a blend of PVP- PVA creates an appropriate balance of the reservoir iodine and free iodine resulting sustained release of iodine from the hydrogel sheets.
  • Such controlled release helps to reduce the toxic side effects of free iodine.
  • PVA/I 2 based less soluble complexes have a unique intrinsic colorimetric indicator which reveals when iodine content is depleted. As iodine depletion occurs, the polymer begins to turn from blue/black, which is the color of the complex, to lighter shades of blue or purple and eventually completely white, indicating that the iodine is depleted and the dressing should be changed.
  • An embodiment of the present invention provides the use of antiseptic macroporous hydrogel sheets as wound dressing and its topical application to small acute wounds, burns, exudative wounds like dermabrasion, chemical peels, superficial burns, laser wounds, friction blisters including epidermolysis bullosa and ulcers.
  • the hydrogel wound dressing can be applied directly to the wounds with or without a supportive dressing.
  • Another embodiment of the present invention provides the use PVP-PEG/I 2 or PVP- PEG-PVA/ I 2 macroporous hydrogel sheet in a bilayer format along with gelatin as the primary layer for skin tissue engineering. This bilayer will help in skin regeneration.
  • An embodiment of the present invention provides the preparation of polymeric matrix by free radical polymerization of N-vinyl pyrrolidone (NVP) at subzero temperatures in presence of a crosslinker.
  • Aqueous solution of the monomer NVP is made by dissolving NVP in water and stirring for some time.
  • the preferred concentration of the monomer is from 2% to 15%.
  • the crosslinker is then added to the aqueous solution and dissolved to get a homogenous solution of the NVP monomer and crosslinker.
  • One of the preferred embodiments of the present invention provides use of polyethyleneglycol diacrylate as crosslinker in the concentration range of 0.5% to 6%.
  • Other cross linkers which may be used divinylpyrrolidone, methylene bis acrylamide.
  • the homogenous aqueous solution was then cooled at 4°C for 30 to 60 min.
  • the monomeric solution was then mixed with free radical activators and initiators.
  • Ammonium persulphate was added as aqueous solution to the above mixture kept under cold conditions.
  • the preferred concentration varies from 0.1 to 0.5 % w/w.
  • N, N', N, N' tetramethylethylene diamine was added.
  • the preferred concentration varies from 0.1% to 0.5% v/v.
  • the NVP monomeric aqueous solutions along with other components were then immediately poured into precooled moulds of desired shape and dimensions and placed at sub zero temperatures in a cryostat.
  • the preferred range of temperature varies from -25°C to -30°C.
  • a preferred mold is a dish of diameter varying from 2mm to 90mm.
  • the mold can be made of any inert non-interactive material, dimensionally stable materials such as stainless steel, polypropylene, higher polyolefins, polyacrylates, polycarbonates, polysulfones, polystyrene and the like which may have coverings of polymer films.
  • the monomeric solution was allowed to polymerize under frozen conditions. As soon as the monomeric solution is frozen at sub zero temperatures most of the liquid phase gets frozen and forms ice crystals. However a small volume of the liquid phase remains unfrozen and contains a highly concentrated solution of all the components added initially.
  • NFLP non- frozen liquid phase
  • the polymerization was found to reach to 90 to 100% completion in 5 to 20 hours depending upon the concentration of the monomer.
  • a stable macroporous hydrogel sheet was formed between 12 to 16 hrs of incubation under frozen condition.
  • the monomers are converted into polymeric chain via free radical polymerization and the polymeric chains were simultaneously crosslinked via the crosslinker leading to the formation of the polymeric hydrogel network along the sides of the ice crystals formed by the liquid phase. After completion of the polymerization the polymerized frozen hydrogels were taken out at room temperature.
  • the thickness of the macroporous hydrogel sheet varied from 0.5mm to 5mm.
  • the resultant PVP-PEG Da hydrogel sheets were elastic, spongy, porous, and had a high swelling ratio and can hold up water upto 80 to 95%.
  • the a eq swelling equilibrium for the polymeric hydrogel varies from 400 to 3000 depending upon the monomer and crosslinker concentrations.
  • the Oeq indicates the capacity of the maximum amount of water that can be retained when dried sheet of the macroporous hydrogel sheet is placed inside an aqueous environment.
  • a yet another embodiment of the present invention provides addition of polyvinylalcohol (PVA) to the polymeric hydrogel sheet of PVP-PEG Da.
  • the PVA may be added at the start of the polymerization to the monomeric solution of N- vinylpyrrolidone.
  • the PVA may be added to the formed macroporous hydrogel sheet of PVP-PEG Da.
  • the polymeric matrix for this macroporous hydrogel sheet has been synthesized by free radical polymerization of N-vinyl pyrrolidone (NVP) at -12 °C in presence of a crosslinker.
  • Aqueous solution of the monomer NVP is made by dissolving NVP in water and stirring for some time. The preferred concentration of the monomer is from 2% to 15%.
  • the crosslinker is then added to the aqueous solution and dissolved to get a homogenous solution of the NVP monomer and crosslinker.
  • a preferred embodiment used polyethyleneglycol as crosslinker in the concentration range of 0.5% to 8%.
  • Other cross linkers which may be used are divinylpyrrolidone, methylene bis acrylamide.
  • the homogenous aqueous solution was ⁇ then cooled at 4 °C for 30 to 60 min. simultaneously an aqueous solution of PVA was also prepared.
  • the proper polymeric matrix for this PVA macroporous hydrogel sheet invention is selected from commercially available PVA's having molecular weights >50,000.
  • PVA aqueous solution is made by heating a mixture of desired concentration of PVA and water preferably at 80° C.
  • the concentration of PVA in water can be as low as 1 % or as high as 20%.
  • the preferred range of PVA concentrations is about 2% to 10%.
  • the PVA aqueous solution and the NVP monomeric solution in water was mixed in equal volumes.
  • the final concentration of the NVP monomer may vary from 1% to 12% and that of PVA from 1% to 20%.
  • the crosslinker concentration and the monomeric solution was then mixed with free radical activators and initiators. Ammonium persulphate was added as aqueous solution to the above mixture kept under cold conditions.
  • the preferred concentration varies from 0.1 to 0.5 % w/w.
  • N, N', N, N' tetramethylethylene diamine was added.
  • the preferred concentration varies from 0.1% to 0.5% v/v.
  • the NVP monomeric aqueous solutions along with PVA solution mixed were then immediately poured into precooled moulds of desired shape and dimensions and placed at sub zero temperatures in a cryostat.
  • the preferred range of temperature varies from 25 to - 30 °C.
  • a preferred embodiment of the mold is a dish of diameter varying from 2mm to 90mm.
  • the mold can be made of any inert non- interactive material, dimensionally stable materials such as stainless steel, polypropylene, higher polyolefins, polyacrylates, polycarbonates, polysulfones, polystyrene and the like which may have coverings of polymer films.
  • the monomeric solution was allowed to polymerize under frozen conditions. As soon as the monomeric solution is frozen at sub zero temperatures most of the liquid phase gets frozen and forms ice crystals. However a small volume of the liquid phase remains unfrozen and contains a highly concentrated solution of all the components added initially. This unfrozen liquid phase is known as non- frozen liquid phase (NFLP) and this where the free radical polymerization of the monomeric solution proceeds. The polymerization was found to reach to 90 to 100% completion in 5 to 20 hours depending upon the concentration of the monomer. Usually we found that a stable macroporous hydrogel sheet was formed between 12 to 16 hrs of incubation under frozen condition.
  • NFLP non- frozen liquid phase
  • the monomers are converted into polymeric chain via free radical polymerization and the polymeric chains were simultaneously crosslinked via the crosslinker leading to the formation of the polymeric hydrogel network along the sides of the ice crystals formed by the liquid phase.
  • the polymerized frozen hydrogels were taken out at room temperature. Thereupon thawing the ice crystals melts and macroporous hydrogel sheet is obtained.
  • the thickness of the macroporous hydrogel sheet varied from 0.5mm to 5mm.
  • the mold and its contents were then subjected to cycles of freezing (0° to -80° C, usually -10° to -25° C.) and thawing (+1 ° to +30° C, usually +20° to +25° C).
  • the number of freeze/thaw cycles can be as low as two or as high as time will allow.
  • the strength of the PVA cryogel elastomer increased with each successive freeze/thaw cycle. Usually we found three to five freeze/thaw cycles were sufficient. The smaller increments of strength gained above five cycles are usually not significant.
  • the durations of each freeze and thaw period can be as little as 2 minutes to as long as 16 hours. We observe that 20 to 30 minutes is all that is normally required.
  • the resultant PVA cryogel shapes are tough, slippery, translucent, elastomeric shapes having 85 to 95% water content.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polymer is polyvinyl pyrrolidone or a combination of polyvinylpyrrolidone and polyvinyl alcohol.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polymer is polyvinyl pyrrolidone or a combination of polyvinylpyrrolidone and polyvinyl alcohol, wherein thickness of the polymer matrix is in the range of about 0.5 mm to 20 mm.
  • the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein pore size of the polymer matrix is in the range of about 1 ⁇ to 250 ⁇ .
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein ratio of the polymer matrix to the iodine is in the range of 2: 1 to 40: lw/w.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein ratio of the polymer matrix to the iodine is 5: 1 w/w.
  • a macroporous polymeric matrix coupled with iodine comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polyethylene glycol diacrylate is in the range of about 2% to 8% w/v, preferably in the range of 2% to 4% w/v.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polyethylene glycol diacrylate is 2%.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polyvinylpyrrolidone is in the range of about 2% to 15% w/v, preferably in the range of 5% to 6% w/v.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polyvinylpyrrolidone is 5% w/v.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polymer matrix comprises polyvinylpyrrolidone and polyvinyl alcohol and polyethyleneglycol diacrylate.
  • a macroporous polymeric matrix coupled with iodine comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polymer matrix comprises polyvinylpyrrolidone, polyvinyl alcohol and polyethyleneglycol diacrylate, wherein ratio of the polyvinylpyrrolidone to the polyvinyl alcohol is in the range of 1 : 1 to 5: 1 preferably 1.25: 1.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polymer matrix is capable of releasing iodine in a sustained manner for a period of 48 hours.
  • a macroporous polymeric matrix coupled with iodine the polymer matrix comprises a polymer cross- linked by polyethyleneglycol diacrylate, wherein the polymer matrix is attached with gelatin.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N-vinyl pyrrolidone at a temperature in the range of about - 10°C to -20°C for a period of about 10 to 20 hours in the presence of polyethylene glycol diacrylate to obtain a polyvinyl pyrrolidone polymer matrix, and incubating the polyvinyl pyrrolidone polymer matrix with iodine at a temperature in the range of about 70°C to 85°C for a period of about 3 to 7 hours to obtain polymer matrix coupled with iodine
  • a process for preparation of a macroporous polymeric matrix coupled with iodine the process comprising polymerizing N-vinyl pyrrolidone at a temperature of about -12°C for a period of about 10 to 20 hours in the presence of polyethylene glycol diacrylate to
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N-vinyl pyrrolidone at a temperature in the range of about - 10°C to -20°C for 16 hours in the presence of polyethylene glycol diacrylate to obtain a polyvinyl pyrrolidone polymer matrix, and incubating the polyvinyl pyrrolidone polymer matrix with iodine at a temperature in the range of about 70°C to 85°C for a period of about 3 to 7 hours to obtain polymer matrix coupled with iodine.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N-vinyl pyrrolidone at a temperature in the range of about - 10°C to -20°C for a period of about 10 to 20 hours in the presence of polyethylene glycol diacrylate to obtain a polyvinyl pyrrolidone polymer matrix, and incubating the polyvinyl pyrrolidone polymer matrix with iodine at a temperature of about 75°C for a period of about 3 to 7 hours to obtain polymer matrix coupled with iodine.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N-vinyl pyrrolidone at a temperature in the range of about - 10°C to -20°C for a period of about 10 to 20 hours in the presence of polyethylene glycol diacrylate to obtain a polyvinyl pyrrolidone polymer matrix, and incubating the polyvinyl pyrrolidone polymer matrix with iodine at a temperature in the range of about 70°C to 85°C for about 5 hours to obtain polymer matrix coupled with iodine.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N- vinylpyrrolidone and polyvinyl alcohol at a temperature in the range of -10°C to -20 °C for a period of about 10 to 20 hours in the presence of polyethyleneglycol diacrylate to obtain a polyvinylpyrrolidone-polyvinyl alcohol polymer matrix, subjecting the polyvinyl pyrrolidone-polyvinyl alcohol polymer matrix at a.temperature in the range of -10°C to -30°C for 5 to 20 hours followed by thawing, and incubating the polyvinylpyrrolidone-polyvinyl alcohol polymer matrix with aqueous iodine at a temperature in the range of about 20°C to 40°C for a period of about 30 minutes to 5 hours to obtain iodine coupled polymer matrix.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N- vinylpyrrolidone and polyvinyl alcohol at a temperature of about -12°C for a period of about 10 to 20 hours in the presence of polyethyleneglycol diacrylate to obtain a polyvinylpyrrolidone-polyvinyl alcohol polymer matrix, subjecting the polyvinyl pyrrolidone-polyvinyl alcohol polymer matrix at a temperature in the range of -10°C to -30°C for 5 to 20 hours followed by thawing, and incubating the polyvinylpyrrolidone-polyvinyl alcohol polymer matrix with iodine at a temperature in the range of about 20°C to 40°C for a period of about 30 minutes to 5 hours to obtain iodine coupled polymer matrix.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N- vinylpyrrolidone and polyvinyl alcohol at a temperature in the range of -10°C to -20 °C for about 16 hours in the presence of polyethyleneglycol diacrylate to obtain a polyvinylpyrrolidone-polyvinyl alcohol polymer matrix, subjecting the polyvinyl pyrrolidone-polyvinyl alcohol polymer matrix at a temperature in the range of -10°C to -30°C for 5 to 20 hours followed by thawing and incubating the polyvinylpyrrolidone-polyvinyl alcohol polymer matrix with iodine at a temperature in the range of about 20°C to 40°C for a period of about 30 minutes to 5 hours to obtain iodine coupled polymer matrix.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N- vinylpyrrolidone and polyvinyl alcohol at a temperature in the range of -10°C to -20 °C for a period of about 10 to 20 hours in the presence of polyethyleneglycol diacrylate to obtain a polyvinylpyrrolidone-polyvinyl alcohol polymer matrix, performing 3-5 cycles preferably 4 cycles of subjecting the polyvinyl pyrrolidone-polyvinyl alcohol polymer matrix to a temperature in the range of -10°C to -30°C for 5 to 20 hours followed by thawing, and incubating the polyvinylpyrrolidone- polyvinyl alcohol polymer matrix with iodine at a temperature in the range of about 20°C to 40°C for a period of about 30 minutes to 5 hours to obtain iodine coupled polymer matrix.
  • a process for preparation of a macroporous polymeric matrix coupled with iodine comprising polymerizing N- vinylpyrrolidone and polyvinyl alcohol at a temperature in the range of -10°C to -20 °C for a period of about 10 to 20 hours in the presence of polyethyleneglycol diacrylate to obtain a polyvinylpyrrolidone-polyvinyl alcohol polymer matrix, subjecting the polyvinyl pyrrolidone-polyvinyl alcohol polymer matrix at a temperature of about -20° for 5 to 20 hours followed by thawing, and incubating the polyvinylpyrrolidone-polyvinyl alcohol polymer matrix with iodine at a temperature in the range of about 20°C to 40°C for a period of about 30 minutes to 5 hours to obtain iodine coupled polymer matrix.
  • the polymer matrix of the present invention comprising active ingredient can be applied directly to the wound with or without a supportive dressing.
  • aqueous solution of the monomer NVP was made by dissolving 5ml of NVP in water in a suitable container and stirring for some time. Then 2ml of polyethylene glycol diacrylate was added to this mixture and stirred to get a homogenous solution. The final volume of the solution was made upto 100ml. The solution was then frozen at -20 C for 30 min and then thawed 30 min. This process was repeated for 3 times. The homogenous aqueous solution was then cooled at 4 °C for 30 to 60 min. The monomeric solution was then mixed with free radical activators and initiators. 200mg of ammonium persulphate was dissolved in 2 ml of water and added as aqueous solution to the above mixture kept under cold conditions.
  • aqueous solution of the monomer NVP was made by dissolving 5ml of NVP in water in a suitable container and stirring for some time. Then 2ml of polyethylene glycol diacrylate was added to this mixture and stirred to get a homogenous solution.
  • the final volume of the solution was made upto 50ml. The solution was then frozen at -
  • the homogenous aqueous solution was then cooled at 4°C for 30 to 60 min. simultaneously an aqueous solution of PVA was also prepared by dissolving 8 g of PVA in 50 ml water.
  • the PVA was dissolved by heating the solution at 90°C for 30 min.
  • the solution was the cooled to room temperature and kept at 4°C for 30 min.
  • the monomeric solution of NVP was mixed with the PVA aqueous solution and then kept on shaker to allow mixing for 15 min. After this solution were incubated at 4 °C for 30 min.
  • the final solution was then mixed with free radical activators and initiators. 200mg of ammonium persulphate was dissolved in 2 ml of water and added as aqueous solution to the above mixture kept under cold conditions.
  • Example 5 Characterization of Polymer matrix Rate of Release of Iodine from PVP-PEG Da -PVA - h and PVP-PEG Da -h The rate of release of iodine from PVP-PEG Da -PVA - I 2 and PVP-PEG Da -I 2 was determined in aqueous system using water. Pre-dried and pre- weighed discs of PVP- PEG Da -PVA - I 2 and PVP-PEG Da -I 2 were placed in 10ml of water in separate compartments. 1ml of water was removed every hour and the released amount of iodine was estimated. Every time same amount of water (that was removed at regular intervals for iodine estimation) was added back to the system.
  • PVP-PEG Da -PVA - I 2 and PVP-PEG Da -I 2 thin sheets of diameter 0.9 cm were placed in LB-agar containing petriplates. Previously petriplates were inoculated with a lawn of respective bacteria namely E.coli and S.aureus (in different petriplates). The plates were then incubated at 37°C for 24 hours. The iodine from the PVP-PEG Da -PVA - I 2 and PVP-PEG Da -I 2 sheets diffused into the surrounding inhibiting the growth of microorganism in that area.
  • the diameter of this zone of inhibition was measured.
  • the macroporous polymeric PVP-PEG Da -PVA - I 2 and PVP-PEG Da -I 2 demostrated good inhibitory activity against both of the strains.
  • the zone of inhibition for PVP-Iodine and PVP-PEG Da -I 2 is 1.7 to 1.9 cm ( Figure 4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une matrice polymère macroporeuse conçue pour administrer un ou plusieurs principes actifs à un sujet qui en a besoin. La matrice polymère comprend un polymère réticulé par du diacrylate de polyéthylène-glycol, le polymère étant un pyrrolidone polyvinylique ou une combinaison de pyrrolidone polyvinylique et d'alcool polyvinylique.
PCT/IN2010/000727 2009-11-05 2010-11-04 Matrice polymère utilisée en tant que pansement WO2011055388A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2275/DEL/2009 2009-11-05
IN2275DE2009 2009-11-05

Publications (2)

Publication Number Publication Date
WO2011055388A2 true WO2011055388A2 (fr) 2011-05-12
WO2011055388A3 WO2011055388A3 (fr) 2011-06-30

Family

ID=43828001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000727 WO2011055388A2 (fr) 2009-11-05 2010-11-04 Matrice polymère utilisée en tant que pansement

Country Status (1)

Country Link
WO (1) WO2011055388A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109620842A (zh) * 2019-02-02 2019-04-16 上海宇昂水性新材料科技股份有限公司 交联聚乙烯吡咯烷酮和碘的络合物及其制备方法与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1867222A (en) 1931-05-16 1932-07-12 Iodine Educational Bureau Inc Surgical material
US3028300A (en) 1960-09-13 1962-04-03 West Laboratories Inc Germicidal compositions and methods for preparing the same
US4128633A (en) 1977-04-27 1978-12-05 Gaf Corporation Process for preparing PVP-iodine complex
US4323557A (en) 1979-07-31 1982-04-06 Minnesota Mining & Manufacturing Company Pressure-sensitive adhesive containing iodine
US4946673A (en) 1984-05-31 1990-08-07 Euroceltique, S.A. Iodine-containing germicidal preparations and method of controlling germicidal activity
US5071648A (en) 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5073614A (en) 1990-10-18 1991-12-17 Isp Investments Inc. Strongly swellable, moderately crosslinked polyvinylpyrrolidone
US5242585A (en) 1991-09-04 1993-09-07 Lenox Institute For Research, Inc. Apparatus and method for deinking waste paper pulp

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769013A (en) * 1982-09-13 1988-09-06 Hydromer, Inc. Bio-effecting medical material and device
US5302385A (en) * 1990-08-20 1994-04-12 Becton, Dickinson And Company Polyurethane-polyvinylpyrrolidone block copolymer and iodine carrier therefrom

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1867222A (en) 1931-05-16 1932-07-12 Iodine Educational Bureau Inc Surgical material
US3028300A (en) 1960-09-13 1962-04-03 West Laboratories Inc Germicidal compositions and methods for preparing the same
US4128633A (en) 1977-04-27 1978-12-05 Gaf Corporation Process for preparing PVP-iodine complex
US4323557A (en) 1979-07-31 1982-04-06 Minnesota Mining & Manufacturing Company Pressure-sensitive adhesive containing iodine
US4946673A (en) 1984-05-31 1990-08-07 Euroceltique, S.A. Iodine-containing germicidal preparations and method of controlling germicidal activity
US5071648A (en) 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5073614A (en) 1990-10-18 1991-12-17 Isp Investments Inc. Strongly swellable, moderately crosslinked polyvinylpyrrolidone
US5242585A (en) 1991-09-04 1993-09-07 Lenox Institute For Research, Inc. Apparatus and method for deinking waste paper pulp

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109620842A (zh) * 2019-02-02 2019-04-16 上海宇昂水性新材料科技股份有限公司 交联聚乙烯吡咯烷酮和碘的络合物及其制备方法与应用
CN109620842B (zh) * 2019-02-02 2021-05-04 上海宇昂水性新材料科技股份有限公司 交联聚乙烯吡咯烷酮和碘的络合物及其制备方法与应用

Also Published As

Publication number Publication date
WO2011055388A3 (fr) 2011-06-30

Similar Documents

Publication Publication Date Title
Singh et al. Radiation synthesis of PVP/alginate hydrogel containing nanosilver as wound dressing
JP4162490B2 (ja) 無水の親水性吸収性創傷用包帯
US5071648A (en) Polymeric broad-spectrum antimicrobial materials
ES2944592T3 (es) Composición para un apósito para heridas
Lei et al. A synergy between dopamine and electrostatically bound bactericide in a poly (vinyl alcohol) hybrid hydrogel for treating infected wounds
CN1089587C (zh) 稳定的交联聚乙烯吡咯烷酮和碘的配合物以及制备该配合物的方法
Finnegan et al. Clinical and antibiofilm efficacy of antimicrobial hydrogels
EP0391741B1 (fr) Matériaux polymères antimicrobiens à large spectre
KR20170107012A (ko) 상처 처치제용 조성물
KR20170107493A (ko) 상처 처치제용 조성물
CN1204929C (zh) 抗菌敷布
CA2882131C (fr) Produits de soin de plaies renfermant des compositions de peracide
Dave et al. Biomedical evaluation of a novel nitrogen oxides releasing wound dressing
JP6157582B2 (ja) 抗菌性および生分解性特性を有する重合体複合材料およびその使用
Yang et al. Inherent antibacterial and instant swelling ε-poly-lysine/poly (ethylene glycol) diglycidyl ether superabsorbent for rapid hemostasis and bacterially infected wound healing
WO2016108041A1 (fr) Compositions anti-biofilm
CA3131379A1 (fr) Traitements antibacteriens de plaies comportant des proprietes favorisant les caillots
US20230180762A1 (en) Composition and methods for antimicrobial articles
US5242985A (en) Aqueous stable complex of a strongly swellable, moderately crosslinked polyvinylpyrrolidone and iodine
WO2011055388A2 (fr) Matrice polymère utilisée en tant que pansement
KR102096254B1 (ko) 유니티올 및 디메틸설폭사이드를 포함하는 방부제 조성물, 조성물의 용도 및 이를 사용하여 상처를 치료하는 방법
Ip Antimicrobial dressings
RU2545735C1 (ru) Биоактивное гидрогелевое раневое покрытие
US20040142020A1 (en) Anhydrous, hydrophilic absorbent wound dressing
Maliyar et al. The Use of Antiseptic and Antibacterial Agents on Wounds and the Skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10801715

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10801715

Country of ref document: EP

Kind code of ref document: A2